BPG is committed to discovery and dissemination of knowledge
Brief Article
©2009 The WJG Press and Baishideng.
World J Gastroenterol. Jan 14, 2009; 15(2): 231-239
Published online Jan 14, 2009. doi: 10.3748/wjg.15.231
Table 5 Therapy and outcome of reported cases of hepatocellular carcinoma associated with autoimmune hepatitis and primary biliary cirrhosis, compared to cases of general hepatocellular carcinoma in Japan
Clinical statusCompiled numbers (%)
P-values
HCC patients with AIH (AIH-series)HCC patients with PBC (PBC-series)General-HCC patientsAIH-series/General-HCC patientsPBC-series/General-HCC patientsAIH-series/PBC-series
Therapy choices for HCCTotal: 38Total: 47Total: 17005Operation vs CL or TAE P = 0.0481RFA, PEIT vs CL or TAE
CL or TAE18 (47.4)17 (36.2)4636 (27.2)RFA,PEIT,MCT vsP = 0.0271
Operation8 (21.0)16 (34.0)5268 (31.0)CL or TAERFA, PEIT vs
RFA, PEIT, MCT6 (15.8)6 (12.8)4890 (28.8)P = 0.0181No therapy
Chemotherapy0 (0)0 (0)765 (4.5)RFA,PEIT,MCT vsP = 0.0032
Others0 (0)0 (0)122 (0.7)No therapy
No therapy6 (15.8)8 (17.0)1324 (7.8)P = 0.0381
Clinical outcomeTotal: 37Total: 49Total: 16646
Alive20 (54.1)31 (63.3)13946 (83.8)P < 0.001bP < 0.001bP = 0.389
Dead17 (45.9)18 (36.7)2700 (16.2)
Cause of deathTotal: 16Total: 18Total: 2700Neoplastic death vs variceal rupture P = 0.0501 Cancer death vs GI bleeding P = 0.0131Neoplastic death vs variceal rupture P = 0.0501
Liver failure8 (50.0)8 (44.4)581 (21.5)
HCC rupture3 (18.8)4 (22.2)172 (6.4)
Variceal rupture1 (6.2)1 (5.6)85 (3.1)
GI bleeding1 (6.2)2 (11.1)55 (2.0)
Neoplastic death0 (0)0 (0)1487 (55.1)
Others3 (18.8)3 (16.7)320 (11.9)


Write to the Help Desk